MannKind

September 05, 2018

United finds a seventh way to serve up treprostinil

Extending a pulmonary hypertension drug’s lifecycle could help battle generic erosion, but investors might have been looking for a more transformative deal.

United finds a seventh way to serve up treprostinil

After Alnylam’s solo maiden launch, here comes the tricky bit

The big launches of 2014 – where are they now?

Mid-cap biopharma stocks pick up in the first quarter

Acorda up, but patent battle looms

Snippet roundup: Christmas comes early for Pfizer’s bankers and Mannkind

Oral insulin could be fools’ gold

Slow Praluent launch another canary in pharma’s coalmine

Fighting over Mannkind’s corpse

Bayer: We wish Mr Brandicourt well

Shifts in consensus leave Novartis's pipeline both a winner and a loser

Latest Reports

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

Editor's Picks

Esmo 2019 preview – Parps on parade

Alzheimer's setbacks have prompted $39bn of market cap losses this year

Should the diabetes development road end for Sanofi?

Six burning Otezla questions

The PCSK9 wars continue, but at what cost?